Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01654380 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2605541 Versus Insulin Glargine on Blood Sugar
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01654380 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 22 participants.
The verdict
NCT01654380, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
LY2605541 is an investigational drug being developed for the treatment of diabetes mellitus. This study is designed to understand how the body handles the investigational drug, what effect this investigational drug has on the body, and how much should be given. This study will also measure how much of the investigational drug gets into the blood stream and how long it takes the body to get rid of it. The study has 2 parts: Part A will be conducted in healthy participants. Part B will be conducted in participants with type 1 diabetes mellitus (T1DM). This study will take approximately 10-14 days spread over 6-20 weeks, not including screening. Screening will be performed within 30 days of the start of the study.
Interventions
- DRUG LY2605541
- OTHER Insulin glargine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01654380
The ClinicalTrials.gov registry entry for NCT01654380 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LY2605541 is the first listed.
NCT01654380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01654380 about?
NCT01654380 is a clinical study titled "A Study of LY2605541 Versus Insulin Glargine on Blood Sugar". LY2605541 is an investigational drug being developed for the treatment of diabetes mellitus. This study is designed to understand how the body handles the investigational drug, what effect this investigational drug has on the body, and how much should be given. This study will also measure how much ...
What is the current status of trial NCT01654380?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2012-07. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01654380?
The interventions under investigation include: LY2605541 (DRUG), Insulin glargine (OTHER).
Who is sponsoring clinical trial NCT01654380?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.